Auryxia FDA Approval History
FDA Approved: Yes (First approved September 5, 2014)
Brand name: Auryxia
Generic name: ferric citrate
Dosage form: Tablets
Company: Keryx Biopharmaceuticals, Inc.
Treatment for: Hyperphosphatemia of Renal Failure, Anemia Associated with Chronic Renal Failure
Auryxia (ferric citrate) is a phosphate binder indicated for the control of serum phosphorus levels in dialysis patients; and an iron replacement product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease who are not on dialysis.
Development timeline for Auryxia
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.